Good morning, ladies and gentlemen.
Thank you for taking time out of your schedules to attend this session. My name is xxx and I am xxx of the NCCHD. NCCHD is a government-related organization that works to promote medicine, especially in the field of pediatrics and obstetrics in Japan and other countries. Our activities include facilitating foreign direct investment into Japan, helping the international xxx of Japan’s small and medium-sized firms, enhancing Japan’s xxx with developing countries and, organizing seminars to encourage international business in high-tech areas. I am delighted that NCCHD has the opportunity to introduce Japan’s cell-based therapy.
We have selected glycoscience as the topic for today’s session. There are several reasons.
Firstly, glycoscience is a cutting-edge life sciences field that has enormous potential for various applications. As you know, glycan microarrays and glycan biomarker provide unique and powerful tools for the development of cancer diagnosis and therapy, as well as regenerative medicine and stem cell-based therapy. There are high expectations for the development of new drugs and practical applications for innovative medicines using these tools.
Secondly, we chose glycoscience because Japan is a pioneer in this key field. The country accounted for xx% of the world’s glycoscience-related patent applications between 20xx and 20xx; this is behind only the Uxx, which accounted for xx% of all applications. Japanese firms have been contributing to the development of innovative medicine using glycoscience. For example, this March, xxx received a exclusive license from xxx, for a therapeutic antibody developed using xxx’s unique glycoscience technology,“xxx”.
Last but not least, glycoscience is an area where we would like to foster and support international tie-ups and collaboration. At this year’s xxx, xx Japanese companies and organizations are exhibiting at the Japan xxx. They present technology and products in the area of glycoscience, including cell engineering, regenerative medicines, microarray and nano-biotech. International collaboration is crucial for high-tech researches, and I hope today’s session will lead you to new opportunities, such as joint research and technology alliances with Japanese exhibitors. We look forward to welcoming all of you to the Japan xxx3.
To conclude, I hope that today’s session will be highly informative on the latest trends in the development and application of glycoscience, and in some way be helpful for your business with Japan in the future.